Small vessels, big trouble in the kidneys and beyond: Hematopoietic stem cell transplantation-associated thrombotic microangiopathy

Blood

Volumn 118, Issue 6, 2011, Pages 1452-1462

  Laskin, Benjamin L ^a   Goebel, Jens ^a   Davies, Stella M ^a   Jodele, Sonata ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCINEURIN; CALCINEURIN INHIBITOR; COMPLEMENT; CREATININE; CYTOKINE; DEFIBROTIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; PROTEIN TYROSINE KINASE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THROMBOMODULIN; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADENOVIRUS INFECTION; ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; ASPERGILLOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOPSY; BLOOD CLOTTING; COMPLEMENT ACTIVATION; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG WITHDRAWAL; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ERYTHEMA INFECTIOSUM; GLOMERULUS FILTRATION RATE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY; HERPES SIMPLEX; HISTOPATHOLOGY; HUMAN; HYPOALBUMINEMIA; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY ISCHEMIA; NONHUMAN; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT WITHDRAWAL;

EID: 80051634380     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-321315     Document Type: Review

References (100)

1. Keir L, Coward RJ. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr Nephrol. 2011;26(4):523-533.
2. Changsirikulchai S, Myerson D, Guthrie KA, McDonald GB, Alpers CE, Hingorani SR. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol. 2009;4(2):345-353.
3. Siami K, Kojouri K, Swisher KK, Selby GB, George JN, Laszik ZG. Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study. Transplantation. 2008;85(1):22-28.
4. Chan GS, Lam MF, Au WY, et al. Clinicopathologic analysis of renal biopsies after haematopoietic stem cell transplantation. Nephrology (Carlton). 2008;13(4):322-330. (Pubitemid 351668331)
5. Batts ED, Lazarus HM. Diagnosis and treatment of transplantation- associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant. 2007;40(8):709-719. (Pubitemid 47521528)
6. George JN. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder. Bone Marrow Transplant. 2008;41(11):917-918. (Pubitemid 351850493)
7. George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion. 2004;44(2):294-304. (Pubitemid 38236394)
8. Perkowska-Ptasinska A, Sulikowska-Rowinska A, Pazik J, Komuda-Leszek E, Durlik M. Thrombotic nephropathy and pulmonary hypertension following autologous bone marrow transplantation in a patient with acute lymphoblastic leukemia: case report. Transplant Proc. 2006;38(1):295-296.
9. Kojouri K, George JN. Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol. 2007;19(2):148-154. (Pubitemid 46204355)
10. Tichelli A, Gratwohl A. Vascular endothelium as 'novel' target of graft-versus-host disease. Best Pract Res Clin Haematol. 2008;21(2):139-148. (Pubitemid 351720432)
11. Chang A, Hingorani S, Kowalewska J, et al. Spectrum of renal pathology in hematopoietic cell transplantation: a series of 20 patients and review of the literature. Clin J Am Soc Nephrol. 2007;2(5):1014-1023.
12. Foley SR, Webert K, Arnold DM, et al. A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney Int Suppl. 2009(112):S55-S58.
13. Laskin BL, Goebel J, Davies SM, et al. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2011;45(5):682-689.
14. Nakamae H, Yamane T, Hasegawa T, et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2006;81(7):525-531.
15. Hale GA, Bowman LC, Rochester RJ, et al. Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. Biol Blood Marrow Transplant. 2005;11(11):912-920. (Pubitemid 41645644)
16. Worel N, Greinix HT, Leitner G, et al. ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: close association with transplant-associated microangiopathy. Transfus Apher Sci. 2007;36(3):297-304. (Pubitemid 47089104)
17. Willems E, Baron F, Seidel L, Frere P, Fillet G, Beguin Y. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. Bone Marrow Transplant. 2010;45(4):689-693.
18. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(8):571-575. (Pubitemid 41001631)
19. Uderzo C, Bonanomi S, Busca A, et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation. 2006;82(5):638-644. (Pubitemid 44395233)
20. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129-1136. (Pubitemid 351398487)
21. Takatsuka H, Takemoto Y, Yamada S, et al. Complications after bone marrow transplantation are manifestations of systemic inflammatory response syndrome. Bone Marrow Transplant. 2000;26(4):419-426. (Pubitemid 30649558)
22. Lopes da Silva R, Ferreira I, Teixeira G, et al. BK virus encephalitis with thrombotic microangiopathy in an allogeneic hematopoietic stem cell transplant recipient. Transpl Infect Dis. 2011;13(2):161-167.
23. Haines HL, Laskin BL, Goebel J, et al. Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation [published online ahead of print March 7, 2011]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2011.02.012.
24. Rosenthal J, Pawlowska A, Bolotin E, et al. Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus. Pediatr Blood Cancer. 2011;57(1):142-146.
25. Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis. 2003;41(2):471-479. (Pubitemid 36152469)
26. Goldberg RJ, Nakagawa T, Johnson RJ, Thurman JM. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis. 2010;56(6):1168- 1174.
27. Thachil J. Nitric oxide in transplantation-related thrombotic microangiopathy. Bone Marrow Transplant. 2009;43(6):513-514.
28. Ponticelli C. De novo thrombotic microangiopathy. An underrated complication of renal transplantation. Clin Nephrol. 2007;67(6):335-340. (Pubitemid 46894796)
29. Rodriguez R, Nakamura R, Palmer JM, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood. 2010;115(5):1098-1105.
30. Cutler C, Henry NL, Magee C, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(7):551-557. (Pubitemid 40862452)
31. Platzbecker U, von Bonin M, Goekkurt E, et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant. 2009;15(1):101-108.
32. Nachbaur D, Schumacher P, Auberger J, Clausen J, Kircher B. Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(8):942-947. (Pubitemid 47055385)
33. Min CK, Kim SY, Lee MJ, et al. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38(2):149-156.
34. Cooke KR, Jannin A, Ho V. The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14(1 Suppl 1):23-32.
35. Biedermann BC. Vascular endothelium and graftversus- host disease. Best Pract Res Clin Haematol. 2008;21(2):129-138. (Pubitemid 351720431)
36. Hingorani SR, Seidel K, Lindner A, Aneja T, Schoch G, McDonald G. Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival. Biol Blood Marrow Transplant. 2008;14(12):1365-1372.
37. Brukamp K, Doyle AM, Bloom RD, Bunin N, Tomaszewski JE, Cizman B. Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease? Clin J Am Soc Nephrol. 2006;1(4):685-694.
38. Cho BS, Min CK, Eom KS, et al. Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(9):813-820.
39. Hingorani S. Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment. J Am Soc Nephrol. 2006;17(7):1995-2005. (Pubitemid 44036184)
40. Mii A, Shimizu A, Masuda Y, et al. Renal thrombotic microangiopathy associated with chronic humoral graft versus host disease after hematopoietic stem cell transplantation. Pathol Int. 2011;61(1):34-41.
41. Nakamura Y, Yujiri T, Ando T, Hisano S, Tanizawa Y. Nephrotic syndrome associated with thrombotic microangiopathy following allogeneic stem-cell transplantation for myelodysplastic syndrome. Br J Haematol. 2007;136(6):857-859. (Pubitemid 46348419)
42. Takatsuka H, Nakajima T, Nomura K, et al. Heparin cofactor II as a predictor of thrombotic microangiopathy after bone marrow transplantation. Hematology. 2006;11(2):101-103. (Pubitemid 43840748)
43. Erdbruegger U, Woywodt A, Kirsch T, Haller H, Haubitz M. Circulating endothelial cells as a prognostic marker in thrombotic microangiopathy. Am J Kidney Dis. 2006;48(4):564-570. (Pubitemid 44402841)
44. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676-1687.
45. Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26(1):41-57.
46. Moore I, Strain L, Pappworth I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115(2):379-387.
47. Zipfel PF, Mache C, Muller D, Licht C, Wigger M, Skerka C. DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr Nephrol. 2010;25(10):2009-2019.
48. Jodele S, Bleesing J, Mehta PA, et al. Successful early intervention for hyperacute transplantassociated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation [published online ahead of print November 5, 2010]. Pediatr Transplant. doi:10.1111/j.1399-3046.2010.01408.
49. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol. 2007;18(4):1046-1056. (Pubitemid 46536891)
50. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352(6):558-569. (Pubitemid 40204669)
51. Eissner G, Multhoff G, Gerbitz A, et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood. 2002;100(1):334-340. (Pubitemid 35177465)
52. Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol. 2008;143(3):336-348.
53. Cho BS, Yahng SA, Lee SE, et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010;90(8):918-926.
54. Schwarz A, Haller H, Schmitt R, et al. Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues. Am J Transplant. 2010;10(9):2017-2025.
55. Troxell ML, Pilapil M, Miklos DB, Higgins JP, Kambham N. Renal pathology in hematopoietic cell transplantation recipients. Mod Pathol. 2008;21(4):396-406. (Pubitemid 351441027)
56. Hewamana S, Austen B, Murray J, Johnson S, Wilson K. Intestinal perforation secondary to haematopoietic stem cell transplant associated thrombotic microangiopathy. Eur J Haematol. 2009;83(3):277.
57. Inamoto Y, Ito M, Suzuki R, et al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transplant. 2009;44(1):43-49.
58. Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplantassociated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92(1):95-100. (Pubitemid 46232661)
59. El-Seisi S, Gupta R, Clase CM, Forrest DL, Milandinovic M, Couban S. Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2003;9(11):683-688. (Pubitemid 38145751)
60. Glezerman IG, Jhaveri KD, Watson TH, et al. Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16(7):976-984.
61. Hingorani S. Chronic kidney disease after pediatric hematopoietic cell transplant. Biol Blood Marrow Transplant. 2008;14(1 Suppl 1):84-87. (Pubitemid 350286856)
62. Qayed M, Thompson A, Applegate K, et al. Is the updated Schwartz formula appropriate for assessing renal function prior to hematopoietic stem cell transplantation? Pediatr Blood Cancer. 2010;55(1):199-201.
63. Muto H, Ohashi K, Ando M, Akiyama H, Sakamaki H. Cystatin C level as a marker of renal function in allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2010;91(3):471-477.
64. Hingorani SR, Guthrie K, Batchelder A, et al. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int. 2005;67(1):272-277. (Pubitemid 40019249)
65. Kanamori H, Takaishi Y, Takabayashi M, et al. Clinical significance of fragmented red cells after allogeneic bone marrow transplantation. Int J Hematol. 2003;77(2):180-184. (Pubitemid 37127572)
66. Ryu J, Lee SR, Park SG, Kang S, Kim HJ, Park BC. Change in serum proteome during allogeneic hematopoietic stem cell transplantation and clinical significance of serum C-reactive protein and haptoglobin. Exp Mol Med. 2010;42(9):651-661.
67. Metzger J, Kirsch T, Schiffer E, et al. Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int. 2010;78(12):1252-1262.
68. Kennedy GA, Bleakley S, Butler J, Mudie K, Kearey N, Durrant S. Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria. Transfusion. 2009;49(9):1884-1889.
69. Choi CM, Schmaier AH, Snell MR, Lazarus HM. Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs. 2009;69(2):183-198.
70. Kennedy GA, Kearey N, Bleakley S, Butler J, Mudie K, Durrant S. Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange. Bone Marrow Transplant. 2010;45(4):699-704.
71. Corti P, Uderzo C, Tagliabue A, et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2002;29(6):542-543. (Pubitemid 34428729)
72. Oran B, Donato M, Aleman A, et al. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant. 2007;13(4):469-477. (Pubitemid 46421891)
73. Hahn T, Alam AR, Lawrence D, et al. Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with doseintensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion. Transplantation. 2004;78(10):1515-1522. (Pubitemid 39552939)
74. Nguyen L, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura, IV: an additional study of 43 consecutive patients, 2005 to 2008. Transfusion. 2009;49(2):392-394.
75. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007;22(5):270-276. (Pubitemid 350013061)
76. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550-1561.
77. Wolff D, Wilhelm S, Hahn J, et al. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graftversus-host disease. Bone Marrow Transplant. 2006;38(6):445-451. (Pubitemid 44340376)
78. Licht C, Weyersberg A, Heinen S, et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis. 2005;45(2):415-421. (Pubitemid 40431070)
79. Marr H, McDonald EJ, Merriman E, et al. Successful treatment of transplant-associated microangiopathy with rituximab. N Z Med J. 2009;122(1292):72-74.
80. Carella AM, D'Arena G, Greco MM, Nobile M, Cascavilla N. Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplant. 2008;41(12):1063-1065. (Pubitemid 352034181)
81. Au WY, Ma ES, Lee TL, et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol. 2007;137(5):475-478. (Pubitemid 46698288)
82. Sakai M, Ikezoe T, Bandobashi K, Togitani K, Yokoyama A. Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant. 2010;45(4):803-805.
83. Naina HV, Gertz MA, Elliott MA. Thrombotic microangiopathy during peripheral blood stem cell mobilization. J Clin Apher. 2009;24(6):259-261.
84. Qu H, Ricklin D, Lambris JD. Recent developments in low molecular weight complement inhibitors. Mol Immunol. 2009;47(2-3):185-195.
85. Nurnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360(5):542-544.
86. Gansevoort RT, de Jong PE. The case for using albuminuria in staging chronic kidney disease. J Am Soc Nephrol. 2009;20(3):465-468.
87. Wuhl E, Trivelli A, Picca S, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639-1650.
88. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a metaanalysis of randomised trials. Lancet. 2009;373(9674):1532-1542.
89. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091-2101.
90. Kersting S, Koomans HA, Hene RJ, Verdonck LF. Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival. Bone Marrow Transplant. 2007;39(6):359-365. (Pubitemid 46403928)
91. Parikh CR, McSweeney P, Schrier RW. Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant. Kidney Int. 2005;67(5):1999-2005. (Pubitemid 40577738)
92. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305.
93. Hoffmeister PA, Hingorani SR, Storer BE, Baker KS, Sanders JE. Hypertension in long-term survivors of pediatric hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16(4):515-524.
94. Cohen EP, Drobyski WR, Moulder JE. Significant increase in end-stage renal disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39(9):571-572. (Pubitemid 46629595)
95. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572-1582. (Pubitemid 44547808)
96. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204-R212.
97. Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007;71(10):1028-1035. (Pubitemid 46741996)
98. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.
99. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137-147.
100. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629-637.